The trial reached each its primary endpoints, with semaglutide two.four mg demonstrating statistically sizeable and outstanding improvements in liver fibrosis without worsening of steatohepatitis, and resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH in comparison